Product References
Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma.
Cancer discovery
Goyal L,Saha SK,Liu LY,Siravegna G,Leshchiner I,Ahronian LG,Lennerz JK,Vu P,Deshpande V,Kambadakone A,Mussolin B,Reyes S,Henderson L,Sun JE,Van Seventer EE,Gurski JM,Baltschukat S,Schacher-Engstler B,Barys L,Stamm C,Furet P,Ryan DP,Stone JR,Iafrate AJ,Getz G,Porta DG,Tiedt R,Bardelli A,Juric D,Corcoran RB,Bardeesy N,Zhu AX
37722 was used in ELISA to determine the molecular basis for acquired resistance to the fibroblast growth factor receptor inhibitor BGJ398
Wed Mar 01 00:00:00 UTC 2017
Phosphorylation of Tyr245 in the open-inhibited state of Abelson kinase does not induce downstream signaling.
European journal of haematology
Skora L,Kempf D,Mestan J,D'Orazio D,Jahnke W
03-7722 was used in ELISA to investigate the role of Tyr245 phosphorylation in Abelson kinase function
Sun May 01 00:00:00 UTC 2016
NMR reveals the allosteric opening and closing of Abelson tyrosine kinase by ATP-site and myristoyl pocket inhibitors.
Proceedings of the National Academy of Sciences of the United States of America
Skora L,Mestan J,Fabbro D,Jahnke W,Grzesiek S
03-7722 was used in an ELISA assay to analyse the solution conformations of Abelson tyrosine kinase (c-Abl) and c-Abl complexes with ATP-site and allosteric inhibitors.
Tue Nov 19 00:00:00 UTC 2013
The small molecule specific EphB4 kinase inhibitor NVP-BHG712 inhibits VEGF driven angiogenesis.
Angiogenesis
Martiny-Baron G,Holzer P,Billy E,Schnell C,Brueggen J,Ferretti M,Schmiedeberg N,Wood JM,Furet P,Imbach P
03-7722 was used in ELISA to develop and characterize an inhibitor of EphB4 kinase
Wed Sep 01 00:00:00 UTC 2010
The small molecule specific EphB4 kinase inhibitor NVP-BHG712 inhibits VEGF driven angiogenesis.
Angiogenesis
Martiny-Baron G,Holzer P,Billy E,Schnell C,Brueggen J,Ferretti M,Schmiedeberg N,Wood JM,Furet P,Imbach P
03-7722 was used in ELISA to develop and characterize an inhibitor of EphB4 kinase
Wed Sep 01 00:00:00 UTC 2010
Increased Level of Phosphorylated ShcA Measured by Chemiluminescence-Linked Immunoassay Is a Predictor of Good Prognosis in Primary Breast Cancer Expressing Low Levels of Estrogen Receptor.
Cancers
Cicenas J,Küng W,Eppenberger U,Eppenberger-Castori S
03-7722 was used in an ELISA assay to study the link between SH2 domain-containing adaptor protein activation, the estrogen receptor, and primary breast cancer prognosis.
Fri Mar 12 00:00:00 UTC 2010
Evaluation of division-arrested cells for cell-based high-throughput screening and profiling.
Journal of biomolecular screening
Digan ME,Pou C,Niu H,Zhang JH
03-7722 was used in an ELISA assay to explore the potential of division-arrested cells as a substitution for dividing cells during cell-based high-throughput screening (HTS).
Thu Sep 01 00:00:00 UTC 2005
In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase.
Cancer cell
García-Echeverría C,Pearson MA,Marti A,Meyer T,Mestan J,Zimmermann J,Gao J,Brueggen J,Capraro HG,Cozens R,Evans DB,Fabbro D,Furet P,Porta DG,Liebetanz J,Martiny-Baron G,Ruetz S,Hofmann F
Mon Mar 01 00:00:00 UTC 2004
AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Cancer research
Traxler P,Allegrini PR,Brandt R,Brueggen J,Cozens R,Fabbro D,Grosios K,Lane HA,McSheehy P,Mestan J,Meyer T,Tang C,Wartmann M,Wood J,Caravatti G
Thu Jul 15 00:00:00 UTC 2004
AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Cancer research
Traxler P,Allegrini PR,Brandt R,Brueggen J,Cozens R,Fabbro D,Grosios K,Lane HA,McSheehy P,Mestan J,Meyer T,Tang C,Wartmann M,Wood J,Caravatti G
Thu Jul 15 00:00:00 UTC 2004